Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Emerging specialists in coagulation have until November 11 to apply for the annual grant program that supports innovative res…
CSL is partnering with the Association of Australian Medical Research Institutes (AAMRI) to sponsor the AAMRI Rising Star Awa…
CSL’s Dr. Greg Kato was part of a team who published a review article about iron restriction in the American Journal of Hemat…
A rare condition, HAE, causes unpredictable swelling attacks that can be life-threatening. Day-to-day, patients live with the…
The organization founded by Philadelphia’s Dr. David Fajgenbaum recently received a big funding boost from a U.S. health agen…
CSL, one of Jumar’s founding partners, celebrated the launch of the state-of-the-art facility, designed to help early-stage b…
Lab automation is helping CSL R&D scientific staff to generate and process data more quickly, enhance reproducibility and be …
CSL is a member of PALADIN, a one-of-a-kind consortium that’s bringing together industry leaders and patient advocacy groups.…
Nature recently talked with CSL’s Roberta Duncan and other experts in the field to explain the innovation of self-amplifying …
CSL has extended its partnership with BaseLaunch, a Basel-area biotech accelerator and incubator for therapeutic ventures.
CSL recently joined the nonprofit organization to strengthen patient engagement in Europe. EUPATI educates and supports patie…
The National Organization for Rare Disorders recently launched a course that explains how a potential treatment becomes an ap…
Americas
Asia Pacific
Middle East
Europe
